Division of Urology, Department of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; Institute of Health Policy, Management, & Evaluation, University of Toronto, Toronto, ON, Canada.
Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
Eur Urol. 2018 Jan;73(1):11-20. doi: 10.1016/j.eururo.2017.05.055. Epub 2017 Jun 11.
Evaluation of treatment options for localized prostate cancer (PCa) remains among the highest priorities for comparative effectiveness research. Surgery and radiotherapy (RT) are the two interventions most commonly used.
To provide a critical narrative review of evidence of the comparative effectiveness and harms of surgery and RT in the treatment of localized PCa.
A collaborative critical narrative review of the literature was conducted.
Evidence to clearly guide treatment choice in PCa remains insufficient. Randomized trials are underpowered for clinically meaningful endpoints and have demonstrated no difference in overall or PCa-specific survival. Observational studies have consistently demonstrated an absolute survival benefit for men treated with radical prostatectomy, but are limited by selection bias and residual confounding errors. Surgery and RT are associated with comparable health-related quality of life following treatment in three randomized trials. Randomized data regarding urinary, erectile, and bowel function show few long-term (>5 yr) differences, although short-term continence and erectile function were worse following surgery and short-term urinary bother and bowel function were worse following RT. There has been recent recognition of other complications that may significantly affect the life trajectory of those undergoing PCa treatment. Of these, hospitalization, the need for urologic, rectoanal, and other major surgical procedures, and secondary cancers are more common among men treated with RT. Androgen deprivation therapy, frequently co-administered with RT, may additionally contribute to treatment-related morbidity. Technological innovations in surgery and RT have shown inconsistent oncologic and functional benefits.
Owing to underpowered randomized control studies and the selection biases inherent in observational studies, the question of which treatment provides better PCa control cannot be definitively answered now or in the near future. Complications following PCa treatment are relatively common regardless of treatment approach. These include the commonly identified issues of urinary incontinence and erectile dysfunction, and others including hospitalization and invasive procedures to manage complications and secondary malignancies. Population-based outcome studies, rather than clinical trial data, will be necessary for a comprehensive understanding of the relative benefits and risks of each therapeutic approach.
Surgery and radiotherapy are the most common interventions for men diagnosed with prostate cancer. Comparisons of survival after these treatments are limited by various flaws in the relevant studies. Complications are common regardless of the treatment approach.
局部前列腺癌 (PCa) 的治疗方案评估仍然是比较疗效研究的重中之重。手术和放疗 (RT) 是最常用的两种干预措施。
提供对手术和 RT 在治疗局部 PCa 中的比较疗效和危害的关键叙述性文献综述。
进行了文献的协作性关键叙述性综述。
仍然缺乏明确指导 PCa 治疗选择的证据。随机试验在有临床意义的终点方面能力不足,并且在总体或 PCa 特异性生存方面没有差异。观察性研究一致表明,接受根治性前列腺切除术治疗的男性具有绝对生存获益,但受到选择偏倚和残留混杂错误的限制。在三项随机试验中,手术和 RT 治疗后与健康相关的生活质量相当。关于尿、勃起和肠道功能的随机数据显示,长期 (>5 年) 差异很少,尽管手术后短期尿控和勃起功能较差,RT 后短期尿困扰和肠道功能较差。最近认识到其他可能显著影响接受 PCa 治疗的人的生活轨迹的并发症。在这些并发症中,接受 RT 治疗的男性更常见的是住院、需要泌尿科、直肠肛门和其他主要手术程序以及继发性癌症。经常与 RT 联合使用的雄激素剥夺疗法可能会额外导致与治疗相关的发病率。手术和 RT 的技术创新显示出不一致的肿瘤学和功能益处。
由于随机对照研究能力不足和观察性研究固有的选择偏倚,现在或不久的将来都无法明确回答哪种治疗方法能更好地控制 PCa。无论治疗方法如何,PCa 治疗后的并发症都相对常见。这些并发症包括常见的尿失禁和勃起功能障碍问题,以及其他包括住院和侵入性手术来管理并发症和继发性恶性肿瘤的问题。基于人群的结局研究而不是临床试验数据,对于全面了解每种治疗方法的相对益处和风险是必要的。
手术和放疗是诊断出患有前列腺癌的男性最常见的干预措施。这些治疗方法后生存比较受到相关研究各种缺陷的限制。无论治疗方法如何,并发症都很常见。